Guru Ownership Trend
Guru Analysis for Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. (PTGX), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q2 2026, a total of 5 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $60.03 M.
Top institutional holders include Stanley Druckenmiller and Ken Fisher.
Institutional sentiment is currently Bullish. This is evidenced by a $3.32 M net inflow during the quarter.
Recent activity highlights Ray Dalio who increased their stake by 75.7%. Conversely, Joel Greenblatt reduced exposure by 11.8%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q2 2026)
Guru Consensus (Q2 2026)
FAQs for Protagonist Therapeutics, Inc. (PTGX)
Major holders include Stanley Druckenmiller ($25.61 M), Ken Fisher ($20.9 M), Joel Greenblatt ($2.29 M). According to the latest reported data, 5 tracked investment managers collectively hold approximately 420,452 shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $3.32 M, with 3 managers increasing positions and 4 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 2 fully exited PTGX. The total reported sell value was $3.35 M.
Yes, 0 managers opened new positions in PTGX, and 3 increased their existing holdings. The total reported buy value was $6.67 M.